ArticleProceedings of the National Academy of Sciences of the United States of America2002
Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 102 citations in OpenAlex.
- Herpesvirus-host interactions in neurological diseases: the immunogenetic role of HLA-E.Journal of virology · 2025Review
- HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.Nature communications · 2025Article
- The MHC (Major Histocmpatibility Complex) Exceptional Molecules of Birds and Their Relationship to Diseases.International journal of molecular sciences · 2025Review
- A monoclonal antibody that recognizes a unique 13-residue epitope in the cytoplasmic tail of HLA-E.Molecular immunology · 2024Article
- Article
- Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies.Frontiers in immunology · 2024Review
- HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD.Blood · 2023Article
- Article
- Changes in HCMV immune cell frequency and phenotype are associated with chronic lung allograft dysfunction.Frontiers in immunology · 2023Article
- New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT).Hematology. American Society of Hematology. Education Program · 2022Article
- Evolution and molecular interactions of major histocompatibility complex (MHC)-G, -E and -F genes.Cellular and molecular life sciences : CMLS · 2022Review
- Distinctive phenotype for HLA-E- versus HLA-A2-restricted memory CD8 αβT cells in the course of HCMV infection discloses features shared with NKG2CFrontiers in immunology · 2022Article
- Mapping and Characterization of HCMV-Specific Unconventional HLA-E-Restricted CD8 T Cell Populations and Associated NK and T Cell Responses Using HLA/Peptide Tetramers and Spectral Flow Cytometry.International journal of molecular sciences · 2021Article
- Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function.The Journal of clinical investigation · 2021Article
- Innate-like NKp30Oncoimmunology · 2021Article
- NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.International journal of molecular sciences · 2020Article
- Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study.The Lancet. Haematology · 2020Article
- Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.Journal of virology · 2019Article
- HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant.Cells · 2019Article
- Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function.BMC immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies showed that a subset of CD8(+) cytolytic T lymphocytes expressing HLA class I-specific natural killer inhibitory receptors (iNKR) is characterized by the ability to recognize HLA-E and to mediate T cell receptor-dependent killing of different NK cell-susceptible tumor target cells. In this study, we show that this CD8(+) T cell subset can also undergo extensive proliferation in mixed lymphocyte cultures in response to allogeneic cells. Analysis of their cytolytic activity revealed a broad specificity against a panel of allogeneic phytohemagglutinin-induced blasts derived from HLA-unmatched donors. On the other hand, autologous and certain allogeneic phytohemagglutinin blasts were resistant to lysis. We used as target cells the transporter associated with antigen processing (TAP)-2(-/-) murine RMA-S cell line cotransfected with beta2-microglobulin and HLA-E*01033. On loading these cells with different HLA-E-binding peptides derived either from HLA class I leader sequences or viral proteins, we could show that HLA-E-specific cytolytic T lymphocytes recognized many, but not all, peptides analyzed. These data suggest that these cells may recognize, on allogeneic cells, HLA-E with peptides that are not present in the host of origin. In addition to their ability to proliferate in response to allogeneic stimulation and to lyse, most allogeneic cells may have important implications in transplantation and in antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.